MET and melanoma: This is probably the reason that very few CAR-T cells against different antigens expressed on melanoma (e.g., VEGFR2, CD70, GD2, c-Met) were tested in clinical trials (NCT03060356, NCT01218867, NCT02107963, NCT02830724).